According to the official website of the Beijing Municipal Government, recently, the Beijing Municipal Science and Technology Commission and the Zhongguancun Science and Technology Park Management Committee issued “Certain Measures to Promote High-Quality Development in the Field of Cell and Gene Therapy”, which aims to promote the high-quality development of the cell and gene therapy industry. The “Measures” focus on the five dimensions of innovation, clinical, platform, supervision, and industry, and launch 9 support measures covering the entire CGT industry chain. Among them, it is specifically proposed to strengthen the full-chain service mechanism for the industrialization of innovative varieties, and that the health insurance department intervene in advance and provide price policy guidance for medical services to prepare for compliance charging conditions in a timely manner after the technology is approved. Listed companies actively lay out cell therapy and revealed their cell therapy layout on the investor interactive platform. Zhongyuan Xiehe said that the company attaches great importance to the international development of the cell therapy business. Dong Fulong said that the company is deeply involved in the field of cell therapy. Kaineng Health said the company has a positive attitude towards the future of the cell industry. Hainan Haiyao said it has formed a collaborative arrangement of “shareholders+cooperation” in the field of cell therapy. Fosun Pharmaceutical said that the CAR-T cell therapy product Yikaida was included in the first edition of the commercial insurance innovative drug catalogue. Bepsis said that a series of recombinant proteins and anti-unique antibody products such as CD19, BCMA, and Her2 developed by the company can be widely used in the CAR-T product development process and testing. In terms of capital, a total of 13 shares have received net financing purchases since August. Pharmaceutical Kangde, Bepsis, and Wisdom Pharmaceutical have the highest net purchase amounts of 342 million yuan, 177 million yuan, and 48 million yuan respectively.

According to the official website of the Beijing Municipal Government, recently, the Beijing Municipal Science and Technology Commission and the Zhongguancun Science and Technology Park Management Committee issued “Certain Measures to Promote High-Quality Development in the Field of Cell and Gene Therapy”, which aims to promote the high-quality development of the cell and gene therapy industry. The “Measures” focus on the five dimensions of innovation, clinical, platform, supervision, and industry, and launch 9 support measures covering the entire CGT industry chain. Among them, it is specifically proposed to strengthen the full-chain service mechanism for the industrialization of innovative varieties, and that the health insurance department intervene in advance and provide price policy guidance for medical services to prepare for compliance charging conditions in a timely manner after the technology is approved. Listed companies actively lay out cell therapy and revealed their cell therapy layout on the investor interactive platform. Zhongyuan Xiehe said that the company attaches great importance to the international development of the cell therapy business. Dong Fulong said that the company is deeply involved in the field of cell therapy. Kaineng Health said the company has a positive attitude towards the future of the cell industry. Hainan Haiyao said it has formed a collaborative arrangement of “shareholders+cooperation” in the field of cell therapy. Fosun Pharmaceutical said that the CAR-T cell therapy product Yikaida was included in the first edition of the commercial insurance innovative drug catalogue. Bepsis said that a series of recombinant proteins and anti-unique antibody products such as CD19, BCMA, and Her2 developed by the company can be widely used in the CAR-T product development process and testing. In terms of capital, a total of 13 shares have received net financing purchases since August. Pharmaceutical Kangde, Bepsis, and Wisdom Pharmaceutical have the highest net purchase amounts of 342 million yuan, 177 million yuan, and 48 million yuan respectively.